Literature DB >> 16228218

Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks.

Luis Arias1, Octavio Pujol, Marcos Rubio, Jose Caminal.   

Abstract

PURPOSE: To evaluate the anatomic-functional results and complications associated with the use of photodynamic therapy (PDT) with verteporfin in the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS).
METHODS: The authors retrospectively evaluated 10 consecutive patients (10 eyes) with CNV secondary to AS. All patients were treated with standard PDT with verteporfin protocol. The primary outcome to evaluate was the proportion of cases that lost < 3 lines of visual acuity (VA) measured on ETDRS charts. Secondary outcomes were changes in the greatest linear dimension (GLD) and in the area of the lesion. Seven previously examined patients were used as a control group.
RESULTS: The mean duration of follow-up was 18 months (SD 9.2, range 6-36 months). In nine cases CNV was subfoveal and in one case, juxtafoveal. Mean VA was 20/126 at baseline (range 20/40-20/320) and 20/500 at the final examination (range 20/64-20/800). Three patients (30%) lost< 3 lines of VA. Four patients (40%) lost > or =6 lines of VA. The mean line change was -4.9 lines. The mean GLD went from 2861 microm at baseline (SD 1086.6, range 1350-4300 microm) to 4452 microm at last visit (SD 2564.2, range 1260-9450 microm). The mean area of the lesion was 3.78 mm(2) at baseline (SD 1.9, range 1.0-5.7 mm(2)) and 12.1 mm(2) at the final examination (SD 15.1, range 0.8-50.6 mm(2)). One patient developed a subfoveal rip of the retinal pigment epithelium. In the control group, the mean duration of follow-up was 15 months (SD 2.4, range 12-18 months). At baseline, the mean VA was 20/160 (range 20/100-20/320) and the mean GLD was 2685 microm (SD 676.8, range 1800-3500 microm). At the last examination, mean VA was 20/640 (range: 20/400-20/800) and mean GLD was 5528 microm (SD 2106.90, range 3500-8000 microm).
CONCLUSION: PDT with verteporfin does not seem to be a good treatment for stabilization of VA and lesion size in CNV secondary to AS, although the overall results seem to be slightly better in the group of patients treated with PDT than in the control group.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16228218     DOI: 10.1007/s00417-005-0131-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  9 in total

1.  Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks.

Authors:  Murat Karacorlu; Serra Karacorlu; Hakan Ozdemir; Cem Mat
Journal:  Am J Ophthalmol       Date:  2002-09       Impact factor: 5.258

2.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors: 
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

3.  Laser treatment of choroidal neovascularization in patients with angioid streaks.

Authors:  J I Lim; N M Bressler; M J Marsh; S B Bressler
Journal:  Am J Ophthalmol       Date:  1993-10-15       Impact factor: 5.258

4.  Laser photocoagulation of choroidal neovascularization in angioid streaks.

Authors:  A Pece; P Avanza; L Galli; R Brancato
Journal:  Retina       Date:  1997       Impact factor: 4.256

5.  A long-term follow-up study of laser coagulation of neovascular membranes in angioid streaks.

Authors:  O Gelisken; F Hendrikse; A F Deutman
Journal:  Am J Ophthalmol       Date:  1988-03-15       Impact factor: 5.258

6.  A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.

Authors:  M Sickenberg; U Schmidt-Erfurth; J W Miller; C J Pournaras; L Zografos; B Piguet; G Donati; H Laqua; I Barbazetto; E S Gragoudas; A M Lane; R Birngruber; H van den Bergh; H A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler
Journal:  Arch Ophthalmol       Date:  2000-03

7.  Outcome of choroidal neovascularization in angioid streaks after photodynamic therapy.

Authors:  Ugo Menchini; Gianni Virgili; Ugo Introini; Francesco Bandello; Massimo Ambesi-Impiombato; Alfredo Pece; Maurizio Battaglia Parodi; Giovanni Giacomelli; Benedetta Capobianco; Monica Varano; Rosario Brancato
Journal:  Retina       Date:  2004-10       Impact factor: 4.256

8.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02

9.  Photodynamic therapy using verteporfin for choroidal neovascularization in angioid streaks.

Authors:  Saad Shaikh; Alan J Ruby; George A Williams
Journal:  Am J Ophthalmol       Date:  2003-01       Impact factor: 5.258

  9 in total
  10 in total

1.  A case of intravitreal bevacizumab injection for the treatment of choroidal neovascularization in angioid streaks.

Authors:  Ji Woong Lee; Jae Pil Shin; Si Yeol Kim
Journal:  Korean J Ophthalmol       Date:  2011-05-24

Review 2.  Verteporfin PDT for non-standard indications--a review of current literature.

Authors:  Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

3.  Intravitreal bevacizumab for choroidal neovascularization secondary to non-age-related macular degeneration.

Authors:  Masoud Salehipour; Nasser Vafi; Azade Doozande; Mehdi Yaseri
Journal:  J Ophthalmic Vis Res       Date:  2010-01

4.  Choroidal neovascularization in angioid streaks following microincision vitrectomy surgery: a case report.

Authors:  Satoshi Katagiri; Takaaki Hayashi; Hirotsugu Takashina; Katsuya Mitooka; Hiroshi Tsuneoka
Journal:  BMC Ophthalmol       Date:  2013-07-05       Impact factor: 2.209

5.  Long-term follow-up of patients with choroidal neovascularization due to angioid streaks.

Authors:  Maria Guadalupe Martinez-Serrano; Abelardo Rodriguez-Reyes; Jose Luis Guerrero-Naranjo; Guillermo Salcedo-Villanueva; Jans Fromow-Guerra; Gerardo García-Aguirre; Virgilio Morales-Canton; Raul Velez-Montoya
Journal:  Clin Ophthalmol       Date:  2016-12-19

6.  Long-term follow-up of choroidal neovascularization secondary to angioid streaks: case series and literature review.

Authors:  Saba Al-Rashaed; J Fernando Arevalo
Journal:  Clin Ophthalmol       Date:  2012-07-05

7.  Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks.

Authors:  Nishant Sachdev; Kavitha Vishwanathan; Vishali Gupta; Ramandeep Singh; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

8.  Angioid streaks, clinical course, complications, and current therapeutic management.

Authors:  Ilias Georgalas; Dimitris Papaconstantinou; Chrysanthi Koutsandrea; George Kalantzis; Dimitris Karagiannis; Gerasimos Georgopoulos; Ioannis Ladas
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

9.  Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks.

Authors:  Jun Mok Lee; Woo Ho Nam; Ha Kyoung Kim
Journal:  Korean J Ophthalmol       Date:  2007-09

Review 10.  Therapy of Pseudoxanthoma Elasticum: Current Knowledge and Future Perspectives.

Authors:  Max Jonathan Stumpf; Nadjib Schahab; Georg Nickenig; Dirk Skowasch; Christian Alexander Schaefer
Journal:  Biomedicines       Date:  2021-12-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.